Clinical Trials
70 trialsStudy of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma
National Cancer Institute (NCI)
Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors
National Cancer Institute (NCI)
Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial
National Institutes of Health Clinical Center (CC)
Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma
National Cancer Institute (NCI)
Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers
National Cancer Institute (NCI)
Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Colon Cancer That Has Not Responded to Vaccine Therapy
National Institutes of Health Clinical Center (CC)
Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery
National Cancer Institute (NCI)
UCN-01 and Prednisone in Treating Patients With Solid Tumors or Lymphoma
National Cancer Institute (NCI)
Acupuncture in Treating Mucositis-Related Pain Caused by Chemotherapy in Patients Undergoing Stem Cell Transplantation
National Cancer Institute (NCI)
LMB-2 Immunotoxin in Treating Young Patients With Relapsed or Refractory Leukemia or Lymphoma
National Cancer Institute (NCI)
Immunotoxin in Treating Patients With Leukemia or Lymphoma
National Cancer Institute (NCI)
Bryostatin 1 and Interleukin-2 in Treating Patients With Refractory Solid Tumors or Lymphoma
National Cancer Institute (NCI)
Flavopiridol in Treating Patients With Refractory Cancer
National Cancer Institute (NCI)
RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors
National Cancer Institute (NCI)
Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia
National Cancer Institute (NCI)
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy
National Cancer Institute (NCI)
Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases
National Cancer Institute (NCI)
Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
National Cancer Institute (NCI)
Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
National Cancer Institute (NCI)
Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction
National Cancer Institute (NCI)
Valproic Acid in Treating Patients With Previously Treated Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
FAU in Treating Patients With Advanced Solid Tumors or Lymphoma
National Cancer Institute (NCI)
Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders
National Cancer Institute (NCI)
Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia
National Cancer Institute (NCI)
Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia
National Cancer Institute (NCI)
Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections
National Cancer Institute (NCI)
Arsenic Trioxide in Treating Patients With Recurrent or Refractory Acute Leukemia, Chronic Myeloide Leukemia, Myelodysplasia, Lymphoma, or Myeloma
National Cancer Institute (NCI)
3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
National Cancer Institute (NCI)
Carbendazim in Treating Patients With Advanced Solid Tumors or Lymphoma
National Cancer Institute (NCI)
AMG 706 and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
National Cancer Institute (NCI)
Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia
National Cancer Institute (NCI)
External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases
National Cancer Institute (NCI)
Study of Information Received About Fertility and Infertility in Patients Who Have Finished Treatment for Cancer
National Cancer Institute (NCI)
Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma
National Cancer Institute (NCI)
MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma
National Cancer Institute (NCI)
VNP40101M in Treating Patients With Advanced Solid Tumors or Lymphomas
National Cancer Institute (NCI)
VNP40101M in Treating Patients With Advanced or Metastatic Cancer
National Cancer Institute (NCI)
AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy
National Cancer Institute (NCI)
17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer
National Cancer Institute (NCI)
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
BCX-1777 in Treating Patients With Refractory Cancer
National Cancer Institute (NCI)
Metformin and Temsirolimus in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma
National Cancer Institute (NCI)
PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma
National Cancer Institute (NCI)
PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
National Cancer Institute (NCI)
Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer
National Cancer Institute (NCI)
Donor Stem Cell Transplant After Conditioning Therapy in Treating Patients With Hematologic Cancer, Recurrent or Metastatic Solid Tumor, or Other Disease
National Cancer Institute (NCI)
Donor Natural Killer Cell Infusion in Preventing Relapse or Graft Failure in Patients Who Have Undergone Donor Bone Marrow Transplant
National Cancer Institute (NCI)
Irinotecan in Treating Patients With Solid Tumors or Lymphoma Who Have Abnormal Liver or Kidney Function or Who Have Received Radiation Therapy to the Pelvis
National Cancer Institute (NCI)
Topotecan and Radiation Therapy in Treating Patients With Solid Tumors or Lymphoma
National Cancer Institute (NCI)